Trial Profile
Treat and Extend Therapy Using Intravitreal Aflibercept (IAI) for Previously Treated Patients Exiting the Wet Age-related Macular Degeneration Extension Study (0910) [EXTENSION OF 700242217]
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Oct 2017
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms RANGE
- 29 Oct 2015 Planned End Date changed from 1 Jul 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov.
- 29 Oct 2015 Planned primary completion date changed to 1 Mar 2016 as reported by ClinicalTrials.gov.
- 02 May 2014 Planned end date changed from 1 Jan 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov.